
Check out expert insight on the most recent lens launches to expand the options accessible to our patients based on their specific needs.

Check out expert insight on the most recent lens launches to expand the options accessible to our patients based on their specific needs.

Brad Sutton, OD, FAAO, FORS, shares highlights from his SCOPA 2022 presentation, "Sleep apnea and the eye."

Brad Sutton, OD, FAAO, FORS, shares highlights from his SCOPA 2022 presentation, "Topical Pharmacology Rounds."

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

Latest transaction, totaling approximately $770 million, adds key commercial products and clinical/preclinical product candidates in the pipeline.

Establish a program in your practice during this Wild West phase of tech.

Results are in for this year's award recipients!

A recent clinical trial from the DRCR Retina Network examined a stepped regimen of anti-VEGF drugs bevacizumab and aflibercept.

Published in Optometry & Visual Sciences, the findings are based on an independent survey featuring feedback from over 500 US eye care professionals.

Studies conducted with Orbis International conclude positive mental health and academic improvements of children provided appropriate eye care and glasses, filling important research gaps and providing essential guidance for future interventions and research.

IBI324 is a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.

Results from a parallel arm study suggest opportunity to expand on visual performance and productivity improvement.

Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.

COMET-3 is the second of 3 studies in the AR-15512 Registrational Phase 3 Program, which is slated for completion by 2023.

The organization has hired Maggie Cline as the new executive director of Utah.

Korean investigators have found intermittent fasting may actually lead to a lower risk of developing AMD in the elderly population.

This year's hybrid interactive conference kicks off in Marco Island, Florida, with expert reporting on advances in treatments and diagnostic tools.

Thomas A. Wong, OD, FNAP, and his co-authors Elise Regina, OD, and Kelly Armstrong, OD, discuss corneal hysteresis: part four.

Consider 4 conditions when treating this patient population.

After surveying over 10,000 professionals from the nation's eyecare workforce, the results are in for this year's top 175 optometrists.

AcuFocus's IC-8 Apthera IOL features a proprietary small aperture technology that filters out peripheral defocused light and allows only focused light to reach the retina.

Lindsay A. Sicks, OD, FAAO, shares her number 1 tip for managing dry eye.

Case gives new perspective on subconjunctival hemorrhages

Diana Canto-Sims, OD, discusses co-op funds with Alessandro Baronti, the president and CEO of the DeRigo Rem.

If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.

The first-of-its-kind alliance and latest phase of AOA's national public awareness campaign focuses on the effects of extended time on digital devices and its impact on eye health.

Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, shares his number 1 tip for managing dry eye.

Current CFO Richard Jones named as interim CEO throughout the search.

A recent study by Orbis International reports that children with myopia experienced significantly higher levels of depression and anxiety than their peers without vision impairment.

Advancements enable better diagnosis, treatment of patients.